Diamyd is forging ahead with a Phase III human trial of DiaPrevent, a potentially new treatment that can stop or slow the destruction of insulin-producing beta cells in the pancreas of people with Type 1 diabetes.
Diamyd recently announced that it has completed the screening of patients for the US trial and has already administered the first injection of either the drug or a placebo to 310 of the 320 patients. They all have Type 1 diabetes and are between the age of 10 and 20 years old. In Phase II studies, the Diamyd therapy has been shown to slow the loss of beta cell function compared to placebo.
The European Phase III study is progressing according to plan, according to Diamyd, with the first results anticipated by the spring of 2011. All patients have received their 4 injections of the drug or placebo, and more than 70% have completed their 15 month visit. When all patients have completed their 15 month visit, the data will be processed and analyzed.
As published by Diabetes Newshound
